Cargando…

Management of portal hypertension and ascites in polycystic liver disease

Patients suffering from polycystic liver disease may develop Hepatic Venous Outflow Obstruction, Portal Vein Obstruction and/or Inferior Caval Vein Syndrome because of cystic mass effect. This can cause portal hypertension, leading to ascites, variceal haemorrhage or splenomegaly. For this review, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernts, Lucas H. P., Drenth, Joost P. H., Tjwa, Eric T. T. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899472/ https://www.ncbi.nlm.nih.gov/pubmed/31505092 http://dx.doi.org/10.1111/liv.14245

Ejemplares similares

Tamoxifen for the treatment of polycystic liver disease: A case report
por: Aapkes, Sophie E., et al.
Publicado: (2021)

Estrogens in polycystic liver disease: A target for future therapies?
por: Aapkes, Sophie E., et al.
Publicado: (2021)

Estrogen‐Containing Oral Contraceptives Are Associated With Polycystic Liver Disease Severity in Premenopausal Patients
por: van Aerts, René M.M., et al.
Publicado: (2019)

Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management
por: Cnossen, Wybrich R, et al.
Publicado: (2014)

Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series
por: Bernts, Lucas H P, et al.
Publicado: (2020)

Urinary Ascites: An Imitator of Portal Hypertension-Related Ascites
por: Zhuang, Tony Z, et al.
Publicado: (2022)

Position statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER
por: Bernts, Lucas H. P., et al.
Publicado: (2019)

Clinical response after laparoscopic fenestration of symptomatic hepatic cysts: a systematic review and meta-analysis
por: Bernts, Lucas H. P., et al.
Publicado: (2018)

Heterozygosity of ALG9 in Association with Autosomal Dominant Polycystic Liver Disease
por: Boerrigter, Melissa M., et al.
Publicado: (2023)

Polycystic Liver Disease and Sarcoidosis: Unusual Coexisting Etiologies of Portal Hypertension
por: Amjad, Waseem, et al.
Publicado: (2017)

Loss of Heterozygosity Is Present in SEC63 Germline Carriers with Polycystic Liver Disease
por: Janssen, Manoe J., et al.
Publicado: (2012)

Quantitative modeling of the physiology of ascites in portal hypertension
por: Levitt, David G, et al.
Publicado: (2012)

Peritoneal lymphoma with ascites mimicking portal hypertensive ascites: A case report
por: Liu, En-Shao, et al.
Publicado: (2019)

Treatment of Polycystic Liver Disease: Impact on Patient-reported Symptom Severity and Health-related Quality of Life
por: Duijzer, Renée, et al.
Publicado: (2022)

Cardiac dysfunction in cirrhotic portal hypertension with or without ascites
por: Dadhich, Sunil, et al.
Publicado: (2014)

Abdominal Pain and Ascites: Not Always Related to Portal Hypertension
por: Nehme, Fredy, et al.
Publicado: (2016)

Portal Hypertension Refractory Ascites Caused by Secondary Hemochromatosis
por: Tie, Jun, et al.
Publicado: (2023)

Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018)

The Evaluation of Serum Ascites Albumin Gradient and Portal Hypertensive changes in Cirrhotic Patients with Ascites
por: Shahed, Forhad Hossain Md, et al.
Publicado: (2016)

Drug holiday in patients with polycystic liver disease treated with somatostatin analogues
por: van Aerts, René M. M., et al.
Publicado: (2018)

Novel GANAB variants associated with polycystic liver disease
por: van de Laarschot, Liyanne F. M., et al.
Publicado: (2020)

Diagnostic utility of the serum–ascites albumin gradient in Mexican patients with ascites related to portal hypertension
por: Cervantes Pérez, Enrique, et al.
Publicado: (2020)

Management of liver disease and portal hypertension in common variable immunodeficiency (CVID)
por: Baumert, Lukas S., et al.
Publicado: (2023)

Differential Clinical Impact of Ascites in Cirrhosis and Idiopathic Portal Hypertension
por: Maruyama, Hitoshi, et al.
Publicado: (2015)

Portal Hypertension and Ascites Due to an Arterioportal Fistula: Sequela of a Remote Traumatic Liver Laceration
por: Hulkower, Benjamin M., et al.
Publicado: (2016)

The Interstitial Lymphatic Peritoneal Mesothelium Axis in Portal Hypertensive Ascites: When in Danger, Go Back to the Sea
por: Aller, M. A., et al.
Publicado: (2010)

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease
por: Gevers, Tom JG, et al.
Publicado: (2012)

Protocol for a randomized controlled multicenter trial assessing the efficacy of leuprorelin for severe polycystic liver disease: the AGAINST-PLD study
por: Aapkes, S. E., et al.
Publicado: (2022)

Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience
por: Pape, Simon, et al.
Publicado: (2020)

Adult Presentation of Noncirrhotic Portal Hypertension and Ascites following Treatment for Wilms’ Tumor in Childhood
por: Kievit, Linda, et al.
Publicado: (2018)

Impact of liver volume on polycystic liver disease-related symptoms and quality of life
por: Neijenhuis, Myrte K, et al.
Publicado: (2017)

Abdominal wall hernia is a frequent complication of polycystic liver disease and associated with hepatomegaly
por: Barten, Thijs R. M., et al.
Publicado: (2022)

Novel α-1,3-Glucosyltransferase Variants and Their Broad Clinical Polycystic Liver Disease Spectrum
por: Boerrigter, Melissa M., et al.
Publicado: (2023)

Ascitic Microbiota Composition Is Correlated with Clinical Severity in Cirrhosis with Portal Hypertension
por: Rogers, Geraint B., et al.
Publicado: (2013)

Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes
por: Rajoriya, Neil, et al.
Publicado: (2016)

The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension
por: Seo, Yeon Seok, et al.
Publicado: (2012)

Giant Splenic Aneurysm with Arteriovenous (A-V) Shunt, Portal Hypertension, and Ascites
por: Ktenidis, Kiriakos, et al.
Publicado: (2018)

Oxaliplatin-related Portal Hypertension Complicated with Esophageal Varices and Refractory Massive Ascites
por: Yazaki, Tomotaka, et al.
Publicado: (2022)

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial
por: Chrispijn, Melissa, et al.
Publicado: (2011)

Endoscopic Management of Portal Hypertension
por: Al-Busafi, Said A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rjssd9gfb2d4fbkl04o1118pge